Melanotan II Peptide Research: 7 Key Findings on MC1R, Pigmentation and Melanocortin Biology
An evidence-based examination of MT2 molecular structure, melanocortin receptor signalling, melanocyte biology, early human studies, safety findings and laboratory analytical standards.
Melanotan II peptide research examines a synthetic cyclic heptapeptide developed from alpha-melanocyte-stimulating hormone (α-MSH). Also called MT2, MT-II or Melanotan 2, the compound was designed to investigate melanocortin receptor activity, particularly its relationship with skin pigmentation and central nervous system responses.
The compound attracted scientific attention because it demonstrated potent melanocortin receptor activity in laboratory studies. Early human experiments also reported increased pigmentation, alongside unexpected physiological effects involving nausea, yawning and sexual responses.
These findings established Melanotan II as an important experimental tool for investigating melanocortin biology. They did not establish it as a safe or approved cosmetic tanning treatment.
Melanotan II peptide research is particularly relevant to the study of MC1R-mediated melanogenesis, MC3R and MC4R signalling, peptide structure–activity relationships and the limitations of translating early pharmacological observations into clinical applications.
Although MT2 has been studied in humans, the available trials were small and conducted decades ago. They do not provide the comprehensive safety and effectiveness evidence required for modern pharmaceutical approval.
This article examines seven findings, distinguishes Melanotan II from related melanocortin compounds and explains why molecular identity, receptor selectivity and experimental context are essential to interpreting the research.
1. Melanotan II Peptide Research: Molecular Structure and Alpha-MSH Origins
Melanotan II is a synthetic analogue of α-MSH, an endogenous peptide involved in melanocortin signalling.
The compound contains seven amino acid residues and has a cyclic structure formed through a side-chain lactam bridge.
Its conventional structural notation is:
Ac-Nle-cyclo[Asp–His–D-Phe–Arg–Trp–Lys]–NH₂
The cyclisation occurs between the side chains of aspartic acid and lysine.
Molecular specifications
| Property | Scientific information |
|---|---|
| Compound | Melanotan II |
| Alternative names | MT2, MT-II, Melanotan 2 |
| Peptide class | Synthetic cyclic heptapeptide |
| Parent signalling family | Alpha-melanocyte-stimulating hormone |
| Structural notation | Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂ |
| Number of residues | 7 |
| Molecular formula | C50H69N15O9 |
| Approximate molecular weight | 1024.2 Da |
| CAS number | 121062-08-6 |
| PubChem CID | 92432 |
| Principal pharmacological class | Nonselective melanocortin receptor agonist |
| FDA approval | Not approved |
These specifications describe the parent compound rather than a particular acetate or other salt preparation.
Why is the peptide cyclic?
The lactam bridge constrains the molecule’s conformation.
Conformational restriction can affect receptor recognition and the stability of particular molecular arrangements.
It does not independently establish long-term biological stability.
What is norleucine?
Norleucine, abbreviated Nle, is a non-proteinogenic amino acid used in some synthetic peptide analogues.
Its inclusion distinguishes Melanotan II from the corresponding natural α-MSH sequence.
Why is D-phenylalanine important?
Melanotan II contains D-phenylalanine rather than the usual L-form found in many naturally occurring peptides.
Stereochemistry can substantially influence receptor affinity and peptide activity.
Is MT2 the same as Melanotan I?
No.
Melanotan I is commonly associated with afamelanotide, a different α-MSH analogue.
The two compounds differ in structure and regulatory status.
Scientific interpretation
Melanotan II peptide research begins with accurate structural identification. Compounds sharing a melanocortin origin cannot be assumed to have identical receptor profiles, clinical effects or safety characteristics.
2. Melanotan II Peptide Research and MC1R-Mediated Pigmentation
The best-known biological effects of Melanotan II concern melanocortin signalling in pigment-producing cells.
What is MC1R?
Melanocortin 1 receptor, abbreviated MC1R, is a G protein-coupled receptor expressed by melanocytes.
Its activation contributes to the regulation of melanin synthesis.
What are melanocytes?
Melanocytes are specialised cells that produce melanin, the pigment responsible for much of the coloration of human skin and hair.
How does MC1R signalling work?
MC1R activation commonly engages Gs-associated signalling.
This can increase intracellular cyclic AMP, which activates downstream processes involving protein kinase A and transcriptional regulation.
What is MITF?
Microphthalmia-associated transcription factor, or MITF, is an important regulator of melanocyte biology.
It contributes to the expression of genes involved in pigmentation.
What is tyrosinase?
Tyrosinase is an enzyme involved in melanin biosynthesis.
Changes in its activity can influence pigment production.
What did early Melanotan II studies report?
An early phase I study involving three male volunteers reported increased pigmentation in two participants following experimental Melanotan II exposure.
The investigators assessed pigmentation through visual observations and quantitative reflectance measurements.
Does increased pigmentation prove protection from skin cancer?
No.
Pigmentation is not equivalent to demonstrated protection from ultraviolet-induced DNA damage or skin cancer.
Does MT2 replace sunscreen?
No.
An experimentally induced change in pigmentation should never be treated as a substitute for established ultraviolet protection measures.
What about existing moles?
Melanocortin-associated pigmentation changes can complicate the appearance and assessment of pigmented skin lesions.
Changes in a mole’s appearance warrant professional medical evaluation rather than assumptions about harmless pigmentation.
Scientific interpretation
Melanotan II peptide research supports the relationship between melanocortin receptor activation and pigmentation. It does not establish MT2 as a safe cosmetic tanning product or a clinically validated skin-cancer prevention strategy.
3. Melanotan II Peptide Research: MC3R, MC4R and Receptor Selectivity
Melanotan II is not an exclusively MC1R-selective compound.
It interacts with multiple melanocortin receptor subtypes.
The melanocortin receptor family
Five receptor subtypes are commonly identified:
- MC1R, associated strongly with pigmentation.
- MC2R, involved in ACTH-dependent adrenal signalling.
- MC3R, involved in central and metabolic signalling.
- MC4R, associated with central neural and metabolic pathways.
- MC5R, expressed in several peripheral tissues.
Does Melanotan II activate all five equally?
No.
Its activity and affinity differ among receptor subtypes.
The compound is generally characterised as a nonselective melanocortin receptor agonist, particularly in relation to MC1R, MC3R, MC4R and MC5R.
What do binding studies show?
Laboratory studies have reported high-affinity interactions with several melanocortin receptors.
However, binding affinity and functional receptor activation are distinct measurements.
What is receptor affinity?
Affinity describes how strongly a compound binds a receptor under defined experimental conditions.
What is functional potency?
Functional potency describes the amount of a compound associated with a specified biological response in an assay.
Why do these measurements differ?
Receptor expression, cellular signalling efficiency and experimental design can influence functional results.
A compound may bind strongly without producing identical responses in every tissue.
Why is MC4R important?
MC4R is expressed in neuronal circuits involved in energy balance, autonomic regulation and motivated behaviour.
Its involvement provides a mechanistic basis for investigating some central effects of melanocortin analogues.
Does MT2 act only through MC4R?
No.
Multiple receptor interactions make it difficult to attribute every observed effect to a single receptor subtype.
Scientific interpretation
Melanotan II peptide research illustrates the importance of receptor selectivity. The same compound can influence pigmentation-related and central physiological pathways through different members of a receptor family.
4. Melanotan II Peptide Research and Early Human Pigmentation Studies
Melanotan II is unusual among experimental peptides because it was examined in human volunteers during early clinical development.
However, the studies were small.
The 1996 phase I study
Dorr and colleagues published a pilot clinical investigation involving three healthy male volunteers.
The study assessed pigmentation and other physiological responses.
What did the researchers observe?
Two participants developed increased pigmentation in selected body regions.
The investigators also reported nausea, fatigue, yawning and other responses.
Why does the sample size matter?
Three participants cannot provide a reliable estimate of uncommon adverse reactions or long-term risks.
What is a phase I study?
Early phase clinical research commonly examines safety, tolerability, pharmacokinetics and preliminary pharmacological effects.
It does not automatically establish treatment effectiveness.
Was the study designed to prove long-term tanning safety?
No.
The experiment did not establish long-term safety for repeated cosmetic exposure.
Were there unexpected effects?
Yes.
The investigators observed physiological responses beyond pigmentation, including spontaneous erections in male volunteers.
These observations helped motivate later studies of melanocortin-associated reproductive physiology.
Can these findings be generalised?
No.
Results from a few volunteers under controlled experimental conditions cannot establish predictable outcomes in a broader population.
Scientific interpretation
Melanotan II peptide research includes direct human observations, but the early pigmentation studies are insufficient to support widespread cosmetic or therapeutic use.
5. Melanotan II Peptide Research and Experimental Sexual Physiology
Historical Melanotan II studies also examined reproductive responses.
These experiments contributed to the broader development of melanocortin pharmacology.
The 1998 controlled study
Wessells and colleagues conducted a double-blind, placebo-controlled crossover study involving ten men with psychogenic erectile dysfunction.
The researchers used objective monitoring to examine erectile responses.
What did the study report?
Eight of the ten participants experienced clinically apparent erections following experimental Melanotan II exposure.
The study also reported differences in measured rigidity compared with placebo.
What were the limitations?
The trial was small, and its findings cannot establish broad clinical safety or effectiveness.
The 2000 research programme
A later report summarised findings from twenty men with psychogenic or organic erectile dysfunction.
Researchers described erectile responses and changes in self-reported desire.
What did the researchers conclude?
The findings supported further investigation of melanocortin receptor agonists in sexual physiology.
Did these studies establish an approved treatment?
No.
Melanotan II did not become an FDA-approved medicine for erectile dysfunction or sexual desire disorders.
Is Melanotan II the same as PT-141?
No.
PT-141, also known as bremelanotide, is a chemically distinct melanocortin analogue.
Why does that distinction matter?
Bremelanotide later underwent its own clinical development programme and received FDA approval for a specific indication.
That approval cannot be transferred to Melanotan II.
Scientific interpretation
Melanotan II peptide research provided early human evidence that melanocortin pathways can influence reproductive physiology. The findings remain distinct from proof of an approved, safe MT2 treatment.
6. Melanotan II Peptide Research: Safety and Adverse Effects
Safety concerns are a major limitation of Melanotan II research.
Historical studies reported several adverse reactions, while regulators have warned against unapproved tanning products containing melanotan compounds.
Nausea
Nausea was frequently reported in early human investigations.
Some participants experienced severe nausea.
Yawning and stretching
Unusual yawning and stretching responses were also described.
These findings illustrate that MT2 can influence physiological systems beyond pigmentation.
Appetite-related effects
Some studies reported reduced appetite.
However, these observations do not establish Melanotan II as a safe or effective weight-management medicine.
Pigmentation changes
Melanocortin activation can alter pigmentation.
Unexpected or changing pigmented lesions require medical assessment.
What about cardiovascular safety?
Small historical studies cannot establish a comprehensive cardiovascular safety profile.
What about contamination?
Unapproved products may have uncertain identity, composition, purity or microbiological quality.
Does a high HPLC purity result establish safety?
No.
Chemical purity cannot establish clinical safety, appropriate formulation or freedom from all relevant contaminants.
Is MT2 approved for cosmetic tanning?
No.
Melanotan II is not FDA-approved for cosmetic tanning or any other therapeutic indication.
Does FDA approval of afamelanotide change this?
No.
Afamelanotide is a different compound used in a specific approved pharmaceutical product.
Its regulatory status does not establish approval or safety for MT2.
Scientific interpretation
Melanotan II peptide research must include adverse effects and regulatory limitations. Describing only pigmentation outcomes would provide an incomplete account of the evidence.
7. Melanotan II Peptide Research: Clinical Evidence Gaps and Future Questions
The available research supports several pharmacological observations, but important uncertainties remain.
Is there evidence of receptor activity?
Yes.
Melanotan II has been studied extensively as a melanocortin receptor agonist.
Has pigmentation been observed in humans?
Yes.
Early clinical studies reported increased pigmentation in small groups of volunteers.
Is long-term cosmetic safety established?
No.
There is insufficient high-quality evidence to establish the safety of long-term cosmetic use.
Has MT2 been proven to prevent skin cancer?
No.
The available evidence does not establish a protective clinical effect against skin cancer.
Is it approved for erectile dysfunction?
No.
Early experimental findings did not lead to an approved Melanotan II medicine.
Are all commercial preparations equivalent?
No.
Differences in chemical form, manufacturing quality and formulation can affect the properties of research materials.
What research would strengthen the evidence?
Useful investigations would include independent replication, detailed receptor-selectivity studies, validated pharmacokinetics and appropriately designed long-term safety assessments.
Why does regulatory status matter?
A compound’s experimental activity does not establish that it meets the standards required for an approved medicine.
Scientific interpretation
Melanotan II peptide research remains relevant to receptor biology and historical drug-development research, but major safety and clinical evidence gaps prevent broad therapeutic conclusions.
Melanotan II Peptide Research: Evidence Summary
| Research area | Evidence available | Appropriate conclusion |
|---|---|---|
| Chemical identity | Established structural data | Cyclic synthetic heptapeptide |
| MC1R interaction | Receptor pharmacology | Pigmentation-associated activity |
| MC3R and MC4R activity | Preclinical receptor studies | Multiple receptor interactions |
| Pigmentation | Small human studies | Increased pigmentation reported |
| Erectile responses | Small controlled human studies | Experimental effects observed |
| Cosmetic tanning safety | Inadequate clinical evidence | Not established |
| Skin-cancer prevention | Insufficient clinical evidence | Not demonstrated |
| Long-term human safety | Inadequate evidence | Unknown |
| FDA approval | Regulatory status | Not approved |
| Research material quality | Batch-dependent | Requires independent verification |
Melanotan II Laboratory Testing: Identity, Purity and Stability
Reliable Melanotan II peptide research requires accurate characterisation of the supplied compound.
This is particularly important because MT2 contains unusual structural features and is available in different chemical forms.
Identity confirmation
Mass spectrometry can support identification by providing evidence consistent with the expected molecular mass.
Additional methods may be necessary to characterise structural and stereochemical features.
HPLC purity
High-performance liquid chromatography can separate the target compound from certain impurities.
However, chromatographic peak-area percentage does not establish absolute peptide content.
LC-MS analysis
Liquid chromatography–mass spectrometry combines separation with mass-based detection.
It can support identity testing and the detection of selected related substances.
Lactam bridge integrity
The cyclic lactam bridge is a defining structural feature.
Incorrectly cyclised or linear material may differ in receptor activity.
D-phenylalanine stereochemistry
The D-phenylalanine residue is another important identity characteristic.
A peptide with altered stereochemistry should not be assumed to behave identically.
Salt forms and counterions
The parent compound and acetate salt have different reported molecular formulas and masses.
Laboratories should confirm which chemical form is being analysed.
Stability testing
Stability depends on the exact formulation, chemical form and environmental conditions.
Storage-life claims require product-specific supporting evidence.
Batch-specific Certificates of Analysis
A useful COA should identify the material, batch number, analytical methods and reported results.
Sterility and endotoxins
Chemical purity and molecular identity do not independently establish sterility or endotoxin status.
These require separate testing where relevant.
Scientific interpretation
Melanotan II peptide research depends on chemical accuracy. An incorrectly identified analogue or degraded sample can compromise the interpretation of receptor experiments.
Worked Example: Interpreting MC1R Signalling Data
Consider a hypothetical laboratory experiment examining cyclic AMP-associated signalling in cells expressing MC1R. Melanotan II peptide research
| Experimental condition | Hypothetical relative signal |
|---|---|
| Untreated control | 1.00 |
| Experimental group A | 1.40 |
| Experimental group B | 2.15 |
| Experimental group C | 2.75 |
These values are fictional and illustrate scientific interpretation only.
What does the table suggest?
The experimental groups show increased signalling compared with the untreated control.
Does this prove specific MC1R activation?
Not by itself.
Receptor-negative controls and appropriate comparative experiments would be needed.
Does a higher signal prove increased melanin production?
No.
Melanin production would need to be measured separately.
Does increased melanin prove ultraviolet protection?
No.
Ultraviolet-related biological outcomes require independent evaluation.
What is the main lesson?
Melanotan II peptide research requires separation of receptor activation, cellular pigmentation measurements and clinical outcomes. Melanotan II peptide research
Melanotan II Compared With Related Melanocortin Peptides
| Compound | Structural distinction | Research or regulatory context |
|---|---|---|
| Melanotan II | Cyclic synthetic α-MSH analogue | Experimental melanocortin agonist; not FDA-approved |
| Afamelanotide | Linear synthetic α-MSH analogue | Approved pharmaceutical ingredient for a specific indication |
| Bremelanotide (PT-141) | Related cyclic melanocortin analogue | Approved pharmaceutical ingredient for a distinct indication |
| Alpha-MSH | Endogenous melanocortin peptide | Physiological pigmentation and receptor signalling |
| ACTH | Endogenous POMC-derived peptide | Adrenal signalling, principally through MC2R |
These compounds share elements of melanocortin biology but differ in structure, pharmacology and clinical evidence.
Related Axion Peptide Lab research guides
Peptide Structure–Activity Relationships
Verify these proposed internal URLs before publishing them as active links.
Melanotan II Research Materials and Axion Peptide Lab
Axion Peptide Lab provides a catalogue relevant to laboratory peptide research.
Researchers examining melanocortin receptor signalling should consult the current catalogue and review available technical specifications and batch documentation. Melanotan II peptide research
What should laboratories verify?
Relevant specifications include the declared chemical structure, peptide sequence, stereochemistry, chemical form, nominal content and batch identification.
Why is structural identity important?
Melanotan II differs from other melanocortin analogues through its particular residue composition and cyclic structure.
Does chromatographic purity establish receptor potency?
No.
Functional receptor activity must be assessed through suitable biological assays.
Does research-only status permit human administration?
No.
Laboratory research materials should not be represented as approved medicines or products intended for human or veterinary administration.
Frequently Asked Questions About Melanotan II Peptide Research
1. What is Melanotan II peptide research?
Melanotan II peptide research examines a synthetic cyclic melanocortin agonist, including its receptor activity, pigmentation-related effects and historical human studies.
2. What is the Melanotan II molecular formula?
The parent compound has the molecular formula C50H69N15O9. Melanotan II peptide research
3. What is the molecular weight of MT2?
The approximate molecular weight of the parent compound is 1024.2 Da.
4. Does Melanotan II activate MC1R?
Yes. Laboratory research demonstrates melanocortin receptor activity, including MC1R-associated signalling.
5. Is Melanotan II selective for MC1R?
No. It interacts with several melanocortin receptor subtypes.
6. Has Melanotan II been studied in humans?
Yes. Small early clinical studies examined pigmentation and reproductive physiological responses.
7. Is Melanotan II FDA-approved?
No. Melanotan II is not an FDA-approved medicine.
8. Does Melanotan II prevent skin cancer?
There is insufficient clinical evidence to establish that it prevents skin cancer.
9. Is Melanotan II the same as PT-141?
No. Melanotan II and bremelanotide are chemically distinct melanocortin analogues. Melanotan II peptide research
10. How can laboratories verify Melanotan II quality?
Relevant methods include HPLC, LC-MS, structural identity testing and batch-specific analytical documentation.
Conclusion: What Melanotan II Peptide Research Establishes
Melanotan II peptide research has contributed to understanding melanocortin receptor signalling, pigmentation biology and selected central physiological responses.
The compound’s molecular identity is well characterised.
Laboratory studies demonstrate activity at multiple melanocortin receptors, while small historical human studies reported changes in pigmentation and reproductive responses.
However, these findings do not establish Melanotan II as a safe cosmetic tanning treatment or an approved therapy.
Its long-term human safety remains inadequately characterised, and adverse effects were reported even in early controlled investigations.
Melanotan II should also be distinguished from afamelanotide and bremelanotide, whose regulatory histories apply to different molecules and specific pharmaceutical products.
For laboratories, accurate chemical identity, suitable analytical methods and careful interpretation of receptor-specific data are essential.
The most defensible conclusion is that Melanotan II remains an important experimental melanocortin agonist, not a clinically validated tanning or therapeutic product. Melanotan II peptide research
Scientific References
- Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME. (1996). Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences.
https://pubmed.ncbi.nlm.nih.gov/8637402/ - Wessells H, Fuciarelli K, Hansen J, Hadley ME, Hruby VJ, Dorr R, Levine N. (1998). Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. The Journal of Urology.
https://doi.org/10.1016/S0022-5347(01)62903-3 - Wessells H, Levine N, Hadley ME, Dorr R, Hruby V. (2000). Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. International Journal of Impotence Research.
https://doi.org/10.1038/sj.ijir.3900582 - Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. (2000).
https://pubmed.ncbi.nlm.nih.gov/11018622/ - PubChem. Melanotan II, CID 92432. Molecular identity, formula and structural information.
https://pubchem.ncbi.nlm.nih.gov/compound/92432 - PubChem. Melanotan II acetate, CID 91971817.
https://pubchem.ncbi.nlm.nih.gov/compound/91971817 - IUPHAR/BPS Guide to Pharmacology. Melanocortin receptor family and ligand pharmacology.
https://www.guidetopharmacology.org/ - PubMed. Melanotan II melanocortin receptor research literature.
https://pubmed.ncbi.nlm.nih.gov/?term=melanotan+II+melanocortin+receptor
These sources support the scientific discussion. They do not verify the quality, safety or regulatory status of independently supplied research materials.
Research-use notice: This article is intended for scientific education and legitimate laboratory research. Axion Peptide Lab research materials are not intended for human or veterinary administration. Melanotan II is not an FDA-approved medicine, and experimental findings should not be interpreted as administration guidance, medical advice or established therapeutic claims.